Today, there is clear evidence from in vivo and in vitro studies that glyburide does not cross the placenta in any appreciable quantity while metformin, another oral glucose-lowering agent, crosses the placenta freely.
What does OGLA stand for?
OGLA stands for Oral Glucose-Lowering Agent (diabetes)
This definition appears very rarely and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of OGLA
We have 3 other meanings of OGLA in our Acronym Attic
- Open Government Licence (UK)
- Open Graphics Library
- Operation Green Leaves (est. 1991)
- Operator Guidelines
- Optimal Guidance Law
- Orientation Group Leader (various organizations)
- Outgoing Links
- Overall Grade Level
- Overlay Generation Language
- Officer Grade Limitations Act
- Oregon Girls Lacrosse Association
- Österreichische Gesellschaft für Landschaftsplanung und Landschaftsarchitektur (German: Austrian Society for Landscape-Design and Landscape-Architecture)
- Outfitters and Guides Licensing Board (Boise, ID)
- Open Gaming License Engine
- Optical Gravitational Lensing Experiment
- Office of Greek Life and Experiential Learning
- Ocean Genome Legacy Foundation (Ipswich, MA)
- One Giant Leap Foundation (est. 2005; space; Tiburon, CA)
- Oslo Gay and Lesbian Film Festival
- Optional Group Life Insurance (Kansas Public Employees Retirement System)
Samples in periodicals archive:
Metformin served as the comparator in determining all-cause mortality risks for the other oral glucose-lowering agents in a multivariate analysis adjusted for age, gender, years of diabetes, cardiovascular medications, and socioeconomic status.
Patients in the study are given pioglitazone at the highest tolerated dose (up to 45 mg) or placebo, with other diabetes medications (non-TZD oral glucose-lowering agents with or without insulin) administered concomitantly.
More information is sorely needed about the possible effects of oral glucose-lowering agents during pregnancy.
Although some recent data suggested that metformin and sulfonylureas are probably not teratogenic, the use of any oral glucose-lowering agent still should be avoided during pregnancy and breast-feeding.
More information is sorely needed about the possible effects of oral glucose-lowering agents during pregnancy Although type 2 diabetes is a growing problem among women of childbearing age, there are virtually no prospective, randomized data about the safety of commonly used oral diabetes drugs on the developing fetus, said Dr.
While 72% of the patients were taking either oral glucose-lowering agents or insulin, 28% were on a statin or other LDL-lowering drug.